Point72 Asset Management L.P. purchased a new stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 3,025,664 shares of the biopharmaceutical company’s stock, valued at approximately $37,760,000.
Other hedge funds also recently made changes to their positions in the company. Meeder Asset Management Inc. purchased a new position in Amicus Therapeutics during the second quarter valued at approximately $73,000. Marshall Wace LLP increased its position in shares of Amicus Therapeutics by 6.9% in the first quarter. Marshall Wace LLP now owns 169,001 shares of the biopharmaceutical company’s stock valued at $2,299,000 after buying an additional 10,911 shares in the last quarter. DekaBank Deutsche Girozentrale increased its position in shares of Amicus Therapeutics by 266.2% in the second quarter. DekaBank Deutsche Girozentrale now owns 244,600 shares of the biopharmaceutical company’s stock valued at $2,935,000 after buying an additional 177,800 shares in the last quarter. First Trust Advisors LP increased its position in shares of Amicus Therapeutics by 424.0% in the second quarter. First Trust Advisors LP now owns 244,550 shares of the biopharmaceutical company’s stock valued at $3,052,000 after buying an additional 197,880 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. increased its position in shares of Amicus Therapeutics by 20.4% in the second quarter. Candriam Luxembourg S.C.A. now owns 886,000 shares of the biopharmaceutical company’s stock valued at $11,009,000 after buying an additional 150,000 shares in the last quarter.
In related news, Director Burke W. Whitman acquired 4,945 shares of the stock in a transaction on Friday, August 23rd. The shares were bought at an average price of $10.07 per share, with a total value of $49,796.15. Following the completion of the purchase, the director now owns 21,612 shares of the company’s stock, valued at approximately $217,632.84. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO John F. Crowley sold 20,000 shares of the business’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $12.54, for a total value of $250,800.00. Following the transaction, the chief executive officer now directly owns 770,194 shares in the company, valued at approximately $9,658,232.76. The disclosure for this sale can be found here. Insiders have sold 60,000 shares of company stock worth $701,200 in the last three months. 2.50% of the stock is currently owned by corporate insiders.
NASDAQ FOLD traded down $0.17 on Friday, reaching $9.45. 4,004,310 shares of the company were exchanged, compared to its average volume of 3,611,713. The business’s fifty day moving average price is $10.24 and its 200 day moving average price is $12.15. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.97 and a current ratio of 7.09. Amicus Therapeutics, Inc. has a fifty-two week low of $8.27 and a fifty-two week high of $14.61.
Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.34). The company had revenue of $44.13 million for the quarter, compared to analyst estimates of $41.14 million. Amicus Therapeutics had a negative return on equity of 66.79% and a negative net margin of 336.41%. The firm’s revenue for the quarter was up 107.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.33) earnings per share. On average, research analysts anticipate that Amicus Therapeutics, Inc. will post -1.39 earnings per share for the current year.
About Amicus Therapeutics
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.
Featured Article: Trading Ex-Dividend Strategy
Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD).
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.